Startup Faze Medicines Inc. launched in early December with a series A funding of $81 million, and an A list of investors, led by Third Rock Ventures – an indicator of the attention condensates are attracting from the biopharma industry. Faze CSO Rachel Meyers, though, named another indicator for condensates’ blue-ribbon status: rumors have it that the 7th edition of Molecular Biology of the Cell – a workhorse textbook for 30 years’ worth of students in the field – will be the first to include information on condensates.
Keeping you up to date on recent developments in oncology, including: Multicancer screening paradigm bolstered in new study; Potentiating PARP inhibitors; New non-viral vector siRNA approach described; NICE nods to combo therapy for HCC.
Investigators at KU Leuven have discovered that although mTOR signaling was important in primary breast tumors and lung metastases alike, the signals that activated mTOR were different between the two, and mTOR signaling could be inhibited through different mechanisms.
Using in vivo imaging technology, investigators at the University of Utah and the University of Padua have identified a new signaling mechanism for glutamate that was linked to the onset of spreading depression or spreading depolarization, a neuronal activity pattern that plays a role in multiple neurological disease states. In mouse models of migraine, glutamate, which is the major excitatory neurotransmitter of the brain, was released in what the authors called "plumes" or puffs.
Ketamine's antidepressant actions depend on the drug's ability to affect mRNA translation, researchers reported in the December 17, 2020, issue of Nature.
Using in vivo imaging technology, investigators at the University of Utah and the University of Padua have identified a new signaling mechanism for glutamate that was linked to the onset of spreading depression or spreading depolarization, a neuronal activity pattern that plays a role in multiple neurological disease states.
Australian biopharma Immutep Ltd. saw its stock price jump 165% Dec. 10, as the company reported that adding its eftilagimod alpha (IMP-321, “efti”) to paclitaxel resulted in what the company called a “promising and improving” trend toward increased overall survival in women with metastatic hormone receptor-driven breast cancer.
Keeping you up to date on recent developments in oncology, including: Study clarifies distinct genomic features of early-onset appendiceal cancer; MET no better than EMT for cancer metastases; MRI may offer risk-stratification for glioblastoma; Study supports short telomeres as protective against cancer.
